Sean McCutcheon
Stock Analyst at Raymond James
(0.38)
# 4,196
Out of 5,006 analysts
10
Total ratings
20%
Success rate
-12.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sean McCutcheon
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Assumes: Strong Buy | $72 | $46.58 | +54.57% | 1 | Sep 12, 2025 | |
| VIR Vir Biotechnology | Initiates: Outperform | $12 | $5.59 | +114.67% | 1 | Jul 11, 2025 | |
| JANX Janux Therapeutics | Initiates: Outperform | $65 | $22.76 | +185.59% | 1 | Jul 11, 2025 | |
| CMPX Compass Therapeutics | Reinstates: Outperform | $9 | $3.67 | +145.23% | 1 | Jul 1, 2025 | |
| BDTX Black Diamond Therapeutics | Reinstates: Outperform | $11 | $3.92 | +180.61% | 1 | Jul 1, 2025 | |
| ENGN enGene Holdings | Initiates: Outperform | $23 | $7.63 | +201.44% | 1 | Nov 27, 2024 | |
| XNCR Xencor | Maintains: Strong Buy | $58 → $40 | $11.79 | +239.27% | 1 | Jun 14, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $92 → $70 | $60.64 | +15.44% | 2 | May 23, 2024 | |
| LEGN Legend Biotech | Initiates: Outperform | $86 | $31.44 | +173.54% | 1 | Mar 13, 2024 |
Revolution Medicines
Sep 12, 2025
Assumes: Strong Buy
Price Target: $72
Current: $46.58
Upside: +54.57%
Vir Biotechnology
Jul 11, 2025
Initiates: Outperform
Price Target: $12
Current: $5.59
Upside: +114.67%
Janux Therapeutics
Jul 11, 2025
Initiates: Outperform
Price Target: $65
Current: $22.76
Upside: +185.59%
Compass Therapeutics
Jul 1, 2025
Reinstates: Outperform
Price Target: $9
Current: $3.67
Upside: +145.23%
Black Diamond Therapeutics
Jul 1, 2025
Reinstates: Outperform
Price Target: $11
Current: $3.92
Upside: +180.61%
enGene Holdings
Nov 27, 2024
Initiates: Outperform
Price Target: $23
Current: $7.63
Upside: +201.44%
Xencor
Jun 14, 2024
Maintains: Strong Buy
Price Target: $58 → $40
Current: $11.79
Upside: +239.27%
Cytokinetics
May 23, 2024
Maintains: Outperform
Price Target: $92 → $70
Current: $60.64
Upside: +15.44%
Legend Biotech
Mar 13, 2024
Initiates: Outperform
Price Target: $86
Current: $31.44
Upside: +173.54%